Lynn MBA - Actinium Pharmaceuticals Chief Officer
| ATNM Stock | USD 1.45 0.02 1.36% |
Executive
Lynn MBA is Chief Officer of Actinium Pharmaceuticals
| Age | 58 |
| Address | 100 Park Avenue, New York, NY, United States, 10017 |
| Phone | 646 677 3870 |
| Web | https://www.actiniumpharma.com |
Actinium Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3091) % which means that it has lost $0.3091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8796) %, meaning that it created substantial loss on money invested by shareholders. Actinium Pharmaceuticals' management efficiency ratios could be used to measure how well Actinium Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 24th of November 2024, Return On Tangible Assets is likely to grow to -0.57. In addition to that, Return On Capital Employed is likely to grow to -0.68. At this time, Actinium Pharmaceuticals' Total Assets are very stable compared to the past year. As of the 24th of November 2024, Total Current Assets is likely to grow to about 82.2 M, while Other Assets are likely to drop 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Frank Yocca | BioXcel Therapeutics | 68 | |
| MD BA | Adaptimmune Therapeutics Plc | 60 | |
| Robyn Hunter | Fortress Biotech | 62 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Amy Pooler | Sangamo Therapeutics | N/A | |
| Patrick MBA | Exelixis | 48 | |
| Cheng Fang | Annovis Bio | N/A | |
| Arndt MD | Affimed NV | 58 | |
| Mark MA | Axsome Therapeutics | 41 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Gregory Davis | Sangamo Therapeutics | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| John Doyle | Cognition Therapeutics | 47 | |
| William MD | Exelixis | N/A | |
| Bobby Horn | Cognition Therapeutics | N/A | |
| Kerry Sharp | Adaptimmune Therapeutics Plc | N/A | |
| Andrew Jones | Eyenovia | 53 | |
| Jeffrey JD | Exelixis | 55 | |
| Richard Barry | Cassava Sciences | 65 | |
| Pablo MD | Kodiak Sciences | N/A | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.31 |
Actinium Pharmaceuticals Leadership Team
Elected by the shareholders, the Actinium Pharmaceuticals' board of directors comprises two types of representatives: Actinium Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Actinium. The board's role is to monitor Actinium Pharmaceuticals' management team and ensure that shareholders' interests are well served. Actinium Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Actinium Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bernie PMP, Executive Management | ||
| Qing Liang, VP Sciences | ||
| Madhuri MD, Vice Therapy | ||
| Lynn MBA, Chief Officer | ||
| Paul Esq, Vice Counsel | ||
| Jenny Hsieh, Chief Officer | ||
| Dr MS, VP Operations | ||
| Sunitha Lakshminarayanan, Head VP | ||
| Mamata Gokhale, Vice President Global Head of Regulatory Affairs | ||
| Arun Swaminathan, Chief Officer | ||
| Elaina Haeuber, VP Operations | ||
| MS MBA, Chairman CEO | ||
| Caroline Yarbrough, Chief Officer | ||
| J Simeon, Executive Assurance | ||
| David Gould, Senior Affairs | ||
| Steven BS, CFO Secretary | ||
| MBA MS, Chairman CEO | ||
| Avinash MD, Chief Officer |
Actinium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Actinium Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.88 | ||||
| Return On Asset | -0.31 | ||||
| Operating Margin | (576.65) % | ||||
| Current Valuation | (31.71 M) | ||||
| Shares Outstanding | 31.2 M | ||||
| Shares Owned By Insiders | 1.78 % | ||||
| Shares Owned By Institutions | 30.10 % | ||||
| Number Of Shares Shorted | 1.45 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 1.18 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Actinium Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Actinium Stock, please use our How to Invest in Actinium Pharmaceuticals guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Actinium Pharmaceuticals. If investors know Actinium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Actinium Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.39) | Revenue Per Share 0.003 | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.88) |
The market value of Actinium Pharmaceuticals is measured differently than its book value, which is the value of Actinium that is recorded on the company's balance sheet. Investors also form their own opinion of Actinium Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Actinium Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Actinium Pharmaceuticals' market value can be influenced by many factors that don't directly affect Actinium Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Actinium Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Actinium Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Actinium Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.